Mineral

Chromium Picolinate

Chromium(III) picolinate

Evidence TierBWADA NOT PROHIBITED

tuneTypical Dose

200-1,000

watchEffect Window

4 to 12 weeks

check_circleCompliance

WADA NOT PROHIBITED

Overview

Clinical Summary

Chromium picolinate provides chromium, a trace mineral linked to insulin signaling and macronutrient metabolism. It is used for modest blood glucose support, especially in insulin resistance.

Trials show small and inconsistent improvements in glucose control and insulin sensitivity, with benefits more likely in type 2 diabetes or low chromium status. Weight effects are generally minimal. Minority findings include modest lipid changes and reduced carbohydrate cravings in some groups. Overall benefit is modest and depends on baseline status and study quality.

Amplifies insulin receptor tyrosine kinase activity via chromodulin signaling. Possible monoamine-related influence on carbohydrate cravings.

Outcomes

What This Is Expected To Influence

Primary Outcomes

  • Improve insulin sensitivity
  • Lower fasting glucose

Secondary Outcomes

  • Reduce carbohydrate cravings

Safety

Contraindications and Interactions

Contraindications

  • Kidney disease
  • Liver disease
  • Chromium allergy

Side effects

  • GI upset
  • Headache

Interactions

  • Insulin/metformin (hypoglycemia risk)
  • Levothyroxine (reduced absorption)
  • NSAIDs (increased chromium absorption)

Avoid if

  • Kidney disease
  • Liver disease
  • Concurrent unmonitored hypoglycemic agents

Evidence

Study-level References

chromium-picolinate-SRC-001Meta-analysis of randomized controlled trials
Sourceopen_in_new

Suksomboon N, et al. 2014 meta-analysis (chromium supplementation in type 2 diabetes)

Population: Adults with type 2 diabetes

Dose protocol: Chromium picolinate 200-1,000 mcg/day over approximately 2-4 months

Key findings: Pooled effects showed approximately -0.55% HbA1c and -20.5 mg/dL fasting glucose.

Notes: Effects are statistically favorable but clinically heterogeneous. Strongest signal appears in insulin-resistant/T2D cohorts.

Paper content

Pooled effects showed approximately -0.55% HbA1c and -20.5 mg/dL fasting glucose.

chromium-picolinate-pmid-41067797Systematic review and meta-analysis of randomized controlled trials.
Sourceopen_in_new

Hamsho M, Ranneh Y, Fadel A. Therapeutic effects of chromium supplementation on women with polycystic ovarian syndrome: A systematic review and meta-analysis. Endocrinol Diabetes Nutr (Engl Ed). 2025;72(8):501578. doi:10.1016/j.endien.2025.501578. PMID:41067797.

Population: Women with polycystic ovarian syndrome across 10 randomized controlled trials.

Dose protocol: Chromium picolinate 200 mcg/day in women with PCOS

Key findings: Significant reductions in fasting insulin, triglycerides, total cholesterol, LDL, and improved insulin sensitivity and ovulation. More effective than metformin for HOMA-IR.

Notes: Meta-analysis of 10 RCTs (683 women). Supports chromium picolinate in a hormone-metabolic population.

Paper content

This meta-analysis pooled data from 10 RCTs (683 women with PCOS) and found that chromium picolinate at 200 mcg/day significantly reduced fasting insulin, triglycerides, total cholesterol, LDL, and prolactin while improving insulin sensitivity and ovulation rates. The analysis also compared chromium directly to metformin and found chromium was more effective at reducing HOMA-IR. The findings support chromium picolinate as an adjunctive intervention for metabolic and reproductive dysfunction in PCOS, though study quality and heterogeneity across included trials should be noted.

chromium-picolinate-pmid-32804855Randomized, double-blind, placebo-controlled trial.
Sourceopen_in_new

Kooshki F, Moradi F, Karimi A, et al. Chromium picolinate balances the metabolic and clinical markers in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled trial. Eur J Gastroenterol Hepatol. 2021;33(10):1298-1306. doi:10.1097/MEG.0000000000001830. PMID:32804855.

Population: Adults aged 20 to 65 years with nonalcoholic fatty liver disease.

Dose protocol: Chromium picolinate 400 mcg/day (200 mcg twice daily) for 12 weeks

Key findings: Improved body weight, body fat, antioxidant capacity, and adipokine markers in NAFLD patients. Liver enzyme between-group differences not confirmed.

Notes: Small RCT (n=46) in NAFLD. Supports metabolic and antioxidant effects of chromium picolinate beyond glycemic markers.

Paper content

This double-blind RCT tested 400 mcg/day chromium picolinate versus placebo for 12 weeks in 46 adults with NAFLD. The chromium group showed significant improvements in body weight, body fat mass, antioxidant markers (total antioxidant capacity, superoxide dismutase, malondialdehyde), and adipokines (leptin decreased, adiponectin increased). Liver enzymes improved within the chromium group but the between-group difference for liver enzymes was not confirmed. The study provides supportive evidence for chromium picolinate as a metabolic adjunct in NAFLD, though the small sample size limits generalizability.

Guides

Setup

Help